| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/03/2003 | CA2461714A1 Treatment of chronic joint inflammation |
| 04/03/2003 | CA2461710A1 Incapacitated whole-cell immunogenic bacterial compositions |
| 04/03/2003 | CA2461705A1 Coadministration of transport protein with conjugated cobalamin to deliver agents |
| 04/03/2003 | CA2461666A1 Combination therapies for immune mediated diseases |
| 04/03/2003 | CA2461631A1 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules |
| 04/03/2003 | CA2461529A1 Recombinant anti-osteopontin antibody and use thereof |
| 04/03/2003 | CA2461421A1 Material consisting of at least a biodegradable polymer and cyclodextrins |
| 04/03/2003 | CA2461305A1 Methods of suppressing microglial activation and systemic inflammatory responses |
| 04/03/2003 | CA2461091A1 Use of hmgb1 for the activation of dendritic cells |
| 04/03/2003 | CA2460953A1 Proteins associated with cell growth, differentiation, and death |
| 04/03/2003 | CA2460780A1 Autologous growth factor cocktail composition, method of production and use |
| 04/03/2003 | CA2460644A1 Methods of sterilizing biological materials containing non-aqueous solvents |
| 04/03/2003 | CA2459807A1 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| 04/03/2003 | CA2453985A1 Receptors and membrane-associated proteins |
| 04/02/2003 | EP1298219A1 Method of assaying the function of fc fragment of antibody |
| 04/02/2003 | EP1298215A2 Recombinant production of immunologically reactive truncated CMV glycoprotein H |
| 04/02/2003 | EP1298211A2 Polynucleotide segment of HPV16 Genome |
| 04/02/2003 | EP1298203A2 Diagnosis and treatment of autoimmune diseases |
| 04/02/2003 | EP1298144A2 Murine monoclonal anti-idiotype antibody 3H1 |
| 04/02/2003 | EP1298139A2 Avian herpes virus-based recombinant infectious bursal disease vaccine |
| 04/02/2003 | EP1297847A2 Anti-CD18 antibodies in stroke |
| 04/02/2003 | EP1297846A1 Method and composition for reconforming multi-epitopic antigens to initiate an immune response |
| 04/02/2003 | EP1297845A2 Toxoid of dermonecrotic toxin produced by bordetella |
| 04/02/2003 | EP1297844A2 Multicomponent meningococcal vaccine |
| 04/02/2003 | EP1297147A2 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 04/02/2003 | EP1297145A2 Streptococcus pyogenes antigen |
| 04/02/2003 | EP1297142A2 Dual specificity antibodies and methods of making and using |
| 04/02/2003 | EP1297139A2 G-protein coupled receptor org10 |
| 04/02/2003 | EP1297135A2 Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| 04/02/2003 | EP1297133A2 Gp354 nucleic acids and polypeptides |
| 04/02/2003 | EP1297130A2 G-protein coupled receptors |
| 04/02/2003 | EP1297129A2 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 04/02/2003 | EP1297128A2 G-protein coupled receptors |
| 04/02/2003 | EP1297118A1 Prostase protein vaccine comprising derivatised thiol residues and methods for producing said antigen |
| 04/02/2003 | EP1297110A1 Attenuated bovine respiratory syncytial virus |
| 04/02/2003 | EP1297017A2 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 04/02/2003 | EP1297013A2 Use of taci as an anti-tumor agent |
| 04/02/2003 | EP1297012A2 Novel fibroblast growth factors and nucleic acids encoding same |
| 04/02/2003 | EP1297011A1 The t-cell protein tzon7, peptides and antibodies derived therefrom and uses thereof |
| 04/02/2003 | EP1297009A2 Tumor-associated antigen b132 |
| 04/02/2003 | EP1297005A2 Immunisation against chlamydia pneumoniae |
| 04/02/2003 | EP1296998A2 Hcv variants |
| 04/02/2003 | EP1296715A2 Multivalent vaccine composition |
| 04/02/2003 | EP1296714A2 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 04/02/2003 | EP1296713A1 Immunostimulatory oligodeoxynucleotides |
| 04/02/2003 | EP1296712A2 Hiv-1 vaccines and screening methods therefor |
| 04/02/2003 | EP1296711A2 Human papilloma virus treatment |
| 04/02/2003 | EP1296710A1 Recombinant vaccines against infectious bursal disease virus |
| 04/02/2003 | EP1296709A1 Solubilised protein vaccines |
| 04/02/2003 | EP1296707A1 Methods of treating viral diseases with il-18 and il-18 combinations |
| 04/02/2003 | EP1296705A1 Neurotoxic oligomers |
| 04/02/2003 | EP1296693A1 Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor. |
| 04/02/2003 | EP1296648A1 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 04/02/2003 | EP1296552A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 04/02/2003 | EP1080206B1 Generation of multiple gene products from chimeric fusion proteins by cleavage with endoproteases |
| 04/02/2003 | EP0991403B1 Use of microparticles with adsorbed antigen to stimulate immune responses |
| 04/02/2003 | EP0946624B1 Biodegradable targetable microparticle delivery system |
| 04/02/2003 | EP0847281B1 Method for detecting or monitoring the effectiveness of treatment of t cell mediated diseases |
| 04/02/2003 | EP0831900B1 Methods of raising antibodies against e.coli of the family cs4-cfa/1 |
| 04/02/2003 | EP0830380B1 Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2, 5-anhydro-d-mannose terminal structure and conjugate vaccine thereof |
| 04/02/2003 | EP0828481B1 Oral dosage composition comprising zonula occludens toxin and a biologically active ingredient and use thereof |
| 04/02/2003 | EP0804283B1 Aqueous solvent encapsulation method and microcapsules |
| 04/02/2003 | EP0804236B1 Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels |
| 04/02/2003 | EP0774513B1 RECOMBINANT HERPESVIRUS WITH THE USE OF gB GENE PROMOTER |
| 04/02/2003 | EP0716697B1 DIFFERENTIALLY EXPRESSED $i(LEISHMANIA) GENES AND PROTEINS |
| 04/02/2003 | EP0700444B1 Immunotoxins comprising gelonin and an antibody |
| 04/02/2003 | EP0696326B1 Use of NDV in the manufacture of a medicament for treating cancer |
| 04/02/2003 | EP0677114B1 Recombinant swinepox virus |
| 04/02/2003 | EP0623169B1 Hepatitis e virus vaccine and method |
| 04/02/2003 | EP0610427B1 Tgf-beta type iii receptor, cdna encoding it and uses therefor |
| 04/02/2003 | EP0561890B1 Dna expression systems based on alphaviruses |
| 04/02/2003 | CN1408021A Recombinant eggs and gene cloning and expression vectors based on avian adenoviruses |
| 04/02/2003 | CN1407901A Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
| 04/02/2003 | CN1407893A Triazinone compounds for treating diseases resulting from infretation with parasitic protozoans |
| 04/02/2003 | CN1407105A Toxoplasmosis composite multi-position genes |
| 04/02/2003 | CN1406950A Human lung cancer antigen and its antibody |
| 04/02/2003 | CN1406629A Vaccin of heterogenous blood vessel endothetial cell growth factor and preparing process thereof |
| 04/02/2003 | CN1406467A Milk with sensitinogen for treating anaphylaxis |
| 04/02/2003 | CN1104501C Modified human C3 proteins |
| 04/02/2003 | CN1104238C Enteric-coated pharmaceutical compositions of mycophenolate |
| 04/01/2003 | US6541616 Exterior membrane; nucleotide sequence; induction immunology response |
| 04/01/2003 | US6541609 Polypeptide having antigenic determinant identical to antigenic determinant of a protein produced by cells infected with simian T-lymphotrophic virus or HTLV-IV, the protein selected from cell-surface glycoproteins, gag proteins |
| 04/01/2003 | US6541459 Soluble herpesvirus glycoprotein complex vaccine |
| 04/01/2003 | US6541458 Sequence of the capsid gene and a corresponding cDNA sequence, of a dominant FCV strain called FCV 431. |
| 04/01/2003 | US6541457 Mammalian IAP gene family, primers, probes and detection methods |
| 04/01/2003 | US6541253 Diagnostics and therapy of diseases associated with HHV-8 infections |
| 04/01/2003 | US6541250 Preferential aggregation; for use in the treatment of melanomas |
| 04/01/2003 | US6541214 N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
| 04/01/2003 | US6541212 Anticancer agents |
| 04/01/2003 | US6541210 Viruses; bacteriophage; Hepatitis B; Hepatitis C; autoimmune disease; use to immunize an organism with a peptide that mimics an antigen or pathogenic organism specific to a disease |
| 04/01/2003 | US6541199 Identification of a new ehrlichia species from a patient suffering from ehrlichiosis |
| 04/01/2003 | US6541046 Herbal composition and method for controlling body weight and composition |
| 04/01/2003 | US6541036 Placing tumor cells in culture in vitro or ex vivo supplemented with pro-apoptotic agent, transferring tumor cells into diffusion chamber, inserting chamber into human for therapeutically effective time |
| 04/01/2003 | US6541011 A recombinant multivalent antigenic polypeptide containing a first antigenic determinant of a first polypeptide and atleast a second antigenic determinant from a second polypeptide |
| 04/01/2003 | US6541009 Viral vaccines |
| 04/01/2003 | US6541007 Vaccine for Pseudomonas aeruginosa |
| 04/01/2003 | US6541003 An immunizing formulation comprising a plasmid encoding an attenuated, doxycycline-inducible proviral molecular clone of the human immunodeficiency virus type 1, and a pharmaceutical carrier |
| 04/01/2003 | US6541001 A stable compacted, compressed or hard tableted vaccine formulation containing a freeze dried antigenic component and a dissolution aid |
| 04/01/2003 | US6541000 Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response |
| 04/01/2003 | US6540999 Administering to patient an antigen, a multivalent conjugate of multiple Lewisx antigen-containing oligosaccharides crosslinked to a carrier molecule and an adjuvant to stimulate a specific antibody response to above antigen |